* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies. 

News and Events

August 9, 2017

Theragnostic Technologies announced today that it has received an SBIR Phase 1 from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/ National Institutes of Health (NIH).

June 8, 2017

Theragnostic Technologies exhibited at Stony Brook's office of Economic Development second annual incubator showcase, Thursday, June 8th. Over 50 company exhibited including representation from the biotechnology, energy and IT industries.

December 28, 2016

Graphene Innovation Investment Fund (Graphene-Invester.com) featured Theragnostic Technologies Graphene-Based MRI Contrast Agent in the article "How Graphene-Based Contrast Agents Improbe MRI Scans".

December 2, 2015

Towards an Advantance Graphene-Based Magnetic Resonance Imaging Contrast Agent: Sub-acute Toxicity and Efficancy Studies in Small Anima ManGraDex publication in Nature Scientific Reports.

October 15, 2015

Theragnostic Technologies Inc has been selected for prestigious NIH Commercialization Accelerator Program (CAP). CAP offered annually since 2004 is designed to help some of  NIH’s most promising healthcare Phase II grantees. Applicants are selected via a competitive process for a limited number of slots.

September 30, 2015

Theragnostic Technologies first product ManGraDex is featured on Research Foundation (RF) of State University of New York (SUNY) website. It discussed on the impact of two business development programs—SUNY’s Technology Accelerator Fund (TAF) and START-UP NY on the development of early stage biomedical technologies.

July 15, 2015

Theragnostic Technologies has received Small Business Innovation Research  (SBIR) Phase 2 grant from the National Institute of Diabestes and Digestive and Kidney Diseases. This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-ased magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure. 

June 5, 2015

Theragnostic Technologies will be introducing ManGraDex MRI technology at the TechConnect Innovation Showcase and Accelerator program, the World’s largest showcase and accelerator for industry-vetted emerging-technologies ready for commercialization. We are seeking to connect with investors and development partners.

 Read Full Press Release

March 24, 2015

Governor Andrew M. Cuomo today announced that Theragnostic Technologies is one of the ten businesses to receive START-UP NY status. Theragnostic joins more than 80 companies already participating in the innovative program that creates tax-free areas associated with colleges and universities across the state. 

READ FULL ARTICLE

September 25, 2013

Theragnostic Technologies  has received Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Diabestes and Digestive and Kidney Diseases in collaboration with  Stony Brook University. This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure.

June 6, 2012

Dr. Balaji Sitharaman, PhD, an Assistant Professor in the Department of Biomedical Engineering at Stony Brook University, and a team of researchers developed a new, highly efficacious, potentially safer and more cost effective nanoparticle-based MRI (magnetic resonance imaging) contrast agent for improved disease diagnosis and detection.

Please reload